冠心宁片辅助治疗老年人冠心病伴失眠症的效果观察  

Efficacy of Guanxinning Tablets as an adjunctive treatment for coronary heart disease complicated by insomnia in older adult patients

作　　者：黄娜 吕雄胜 梅健华 Huang Na;Lyu Xiongsheng;Mei Jianhua(Department of Geriatrics,The Second People's Hospital of Lishui,Lishui 323000,Zhejiang Province,China)

机构地区：[1]丽水市第二人民医院老年科,丽水323000

出　　处：《中国基层医药》2025年第2期172-176,共5页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省医学会临床科研基金(2021ZYC-A239)。

摘　　要：目的探讨冠心宁片辅助治疗对老年人冠心病伴失眠症的临床效果。方法选取丽水市第二人民医院2021年12月至2023年12月收治的冠心病伴失眠症患者80例为研究对象, 采用随机病例对照研究方法, 根据随机数字表法分为对照组、观察组各40例。对照组接受常规治疗及促进睡眠的基础干预, 观察组对照组基础上联用冠心宁片, 两组疗程8周。比较两组治疗效果、心绞痛发作频次和疼痛持续时间、匹兹堡睡眠质量指数(PSQI)评分、西雅图心绞痛量表(SAQ)评分、血清白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、血管内皮生长因子(VEGF)水平变化及不良反应发生率。结果观察组临床疗效高于对照组(Z=2.07, P < 0.05)。治疗后, 观察组心绞痛发作频次、疼痛持续时间分别为(1.02±0.31)次/d、(1.35±0.27)min, 均少于、短于对照组的(1.54±0.40)次/d、(1.71±0.36)min(t=-6.50、-5.06, 均P < 0.05);观察组PSQI评分为(5.93±1.28)分, 低于对照组的(7.33±2.05)分(t=-3.66, P < 0.05);观察组SAQ量表各维度评分均高于对照组(t=2.81、2.30、2.97、4.76、4.24, 均P < 0.05);观察组IL-6、TNF-α分别为(13.48±3.60)mg/L、(15.53±3.83)μg/L, 均低于对照组的(16.26±4.51)mg/L、(20.38±3.92)μg/L, 观察组VEGF为(128.26±16.67)ng/L, 高于对照组的(105.78±14.35)ng/L, 两组比较, 差异均有统计学意义(t=-3.05、-5.60、6.46, 均P < 0.05)。两组不良反应发生率差异无统计学意义(P > 0.05)。结论冠心宁片辅助治疗对老年人冠心病伴失眠症疗效显著, 可缓解患者的心绞痛症状, 提高睡眠质量, 降低炎症反应, 且不增加药物不良反应。Objective:To investigate the efficacy of Guanxinning Tablets as an adjunctive treatment for coronary heart disease complicated by insomnia in older adult patients.Methods:A total of 80 patients with coronary heart disease complicated by insomnia,admitted to The Second People's Hospital of Lishui between December 2021 and December 2023,were selected for this study.A randomized,controlled trial design was used,with patients randomly assigned to either the control group or the observation group(n=40/group).The control group received conventional treatment along with basic sleep-promoting interventions,while the observation group received Guanxinning Tablets in addition to the treatment provided to the control group.The treatment duration for both groups was 8 weeks.The therapeutic effects,frequency and duration of angina attacks,Pittsburgh Sleep Quality Index score,Seattle Angina Questionnaire score,serum levels of interleukin-6,tumor necrosis factor-alpha,vascular endothelial growth factor,and the incidence of adverse reactions were compared between the two groups.Results:The clinical efficacy of the observation group was significantly better than that of the control group(Z=2.07,P<0.05).After treatment,the frequency and duration of angina attacks in the observation group were(1.02±0.31)times/d and(1.35±0.27)min,both of which were significantly lower and shorter than those in the control group[(1.54±0.40)times/d,(1.71±0.36)min,t=-6.50,-5.06,both P<0.05].The Pittsburgh Sleep Quality Index score in the observation group was(5.93±1.28),which was significantly lower than that in the control group[(7.33±2.05),t=-3.66,P<0.05].The Seattle Angina Questionnaire scores for all dimensions in the observation group were higher than those in the control group(t=2.81,2.30,2.97,4.76,4.24,all P<0.05).The levels of interleukin-6 and tumor necrosis factor-alpha in the observation group were(13.48±3.60)mg/L and(15.53±3.83)μg/L,respectively,both of which were significantly lower than those in the control group[(16.26±4.51)mg/

关 键 词：冠状动脉疾病 心绞痛 入睡和睡眠障碍 白细胞介素6 肿瘤坏死因子Α 血管内皮生长因子类 老年人 

分 类 号：R541.4[医药卫生—心血管疾病] R740[医药卫生—内科学]